{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T18:29:25Z","timestamp":1761676165913},"reference-count":55,"publisher":"Elsevier BV","issue":"19","content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1016\/j.vaccine.2014.02.056","type":"journal-article","created":{"date-parts":[[2014,3,11]],"date-time":"2014-03-11T20:46:28Z","timestamp":1394570788000},"page":"2173-2180","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["As a genetic adjuvant, CTA improves the immunogenicity of DNA vaccines in an ADP-ribosyltransferase activity- and IL-6-dependent manner"],"prefix":"10.1016","volume":"32","author":[{"given":"Yanmin","family":"Wan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaonan","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanqin","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhidong","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyan","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianqing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2014.02.056_bib0005","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/infdis\/125.6.672","article-title":"Adjuvant effect of cholera enterotoxin on the immune response of the mouse to sheep red blood cells","volume":"125","author":"Northrup","year":"1972","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2014.02.056_bib0010","first-page":"179","article-title":"Cholera toxin: a paradigm of a multifunctional protein","volume":"133","author":"Bharati","year":"2011","journal-title":"Indian J Med Res"},{"key":"10.1016\/j.vaccine.2014.02.056_bib0015","doi-asserted-by":"crossref","first-page":"6408","DOI":"10.4049\/jimmunol.169.11.6408","article-title":"Restraint of proinflammatory cytokine biosynthesis by mitogen-activated protein kinase phosphatase-1 in lipopolysaccharide-stimulated macrophages","volume":"169","author":"Chen","year":"2002","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2014.02.056_bib0020","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/mi.2010.16","article-title":"Gene expression profiling identifies STAT3 as a novel pathway for immunomodulation by cholera toxin adjuvant","volume":"3","author":"Sj\u00f6blom-Hall\u00e9n","year":"2010","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.vaccine.2014.02.056_bib0025","doi-asserted-by":"crossref","first-page":"10638","DOI":"10.1073\/pnas.1002348107","article-title":"Mucosal adjuvant activity of cholera toxin requires Th17 cells and protects against inhalation anthrax","volume":"107","author":"Datta","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vaccine.2014.02.056_bib0030","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1128\/CMR.8.1.48","article-title":"Cholera","volume":"8","author":"Kaper","year":"1995","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.vaccine.2014.02.056_bib0035","doi-asserted-by":"crossref","first-page":"3936","DOI":"10.4049\/jimmunol.158.8.3936","article-title":"Genetically engineered nontoxic vaccine adjuvant that combines B cell targeting with immunomodulation by cholera toxin A1 subunit","volume":"158","author":"Agren","year":"1997","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2014.02.056_bib0040","doi-asserted-by":"crossref","DOI":"10.1038\/mi.2013.16","article-title":"The immune complex CTA1-DD\/IgG adjuvant specifically targets connective tissue mast cells through FcgammaRIIIA and augments anti-HPV immunity after nasal immunization","author":"Fang","year":"2013","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.vaccine.2014.02.056_bib0045","doi-asserted-by":"crossref","first-page":"3951","DOI":"10.1016\/j.vaccine.2011.03.090","article-title":"A novel non-toxic combined CTA1-DD and ISCOMS adjuvant vector for effective mucosal immunization against influenza virus","volume":"29","author":"Eliasson","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.02.056_bib0050","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.4049\/jimmunol.1002881","article-title":"A unique role of the cholera toxin A1-DD adjuvant for long-term plasma and memory B cell development","volume":"186","author":"Bemark","year":"2011","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2014.02.056_bib0055","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/mi.2010.54","article-title":"Mucosal adjuvants and long-term memory development with special focus on CTA1-DD and other ADP-ribosylating toxins","volume":"3","author":"Lycke","year":"2010","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.vaccine.2014.02.056_bib0060","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.4049\/jimmunol.1000589","article-title":"Mast cells contribute to the mucosal adjuvant effect of CTA1-DD after IgG-complex formation","volume":"185","author":"Fang","year":"2010","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2014.02.056_bib0065","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jri.2009.04.002","article-title":"CTA1-DD is an effective adjuvant for targeting anti-chlamydial immunity to the murine genital mucosa","volume":"81","author":"Cunningham","year":"2009","journal-title":"J Reprod Immunol"},{"key":"10.1016\/j.vaccine.2014.02.056_bib0070","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1002\/art.24566","article-title":"Role of CTA1R7K-COL-DD as a novel therapeutic mucosal tolerance-inducing vector for treatment of collagen-induced arthritis","volume":"60","author":"Hasselberg","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.vaccine.2014.02.056_bib0075","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1099\/vir.0.2008\/005470-0","article-title":"CTA1-DD adjuvant promotes strong immunity against human immunodeficiency virus type 1 envelope glycoproteins following mucosal immunization","volume":"89","author":"Sundling","year":"2008","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2014.02.056_bib0080","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.vaccine.2007.12.027","article-title":"CTA1-M2e-DD: a novel mucosal adjuvant targeted influenza vaccine","volume":"26","author":"Eliasson","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.02.056_bib0085","doi-asserted-by":"crossref","first-page":"6224","DOI":"10.1016\/j.vaccine.2007.05.065","article-title":"Intrarectal immunization of mice with VP6 and either LT(R192G) or CTA1-DD as adjuvant protects against fecal rotavirus shedding after EDIM challenge","volume":"25","author":"McNeal","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.02.056_bib0090","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1128\/IAI.01290-06","article-title":"The combined CTA1-DD\/ISCOMs vector is an effective intranasal adjuvant for boosting prior Mycobacterium bovis BCG immunity to Mycobacterium tuberculosis","volume":"75","author":"Andersen","year":"2007","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2014.02.056_bib0095","doi-asserted-by":"crossref","first-page":"3697","DOI":"10.4049\/jimmunol.176.6.3697","article-title":"The combined CTA1-DD\/ISCOM adjuvant vector promotes priming of mucosal and systemic immunity to incorporated antigens by specific targeting of B cells","volume":"176","author":"Helgeby","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2014.02.056_bib0100","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1365-3083.2005.01713.x","article-title":"The nontoxic CTA1-DD adjuvant enhances protective immunity against Helicobacter pylori infection following mucosal immunization","volume":"63","author":"Akhiani","year":"2006","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.vaccine.2014.02.056_bib0105","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.vaccine.2005.08.061","article-title":"The universal influenza vaccine M2e-HBc administered intranasally in combination with the adjuvant CTA1-DD provides complete protection","volume":"24","author":"De Filette","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.02.056_bib0110","doi-asserted-by":"crossref","first-page":"3310","DOI":"10.4049\/jimmunol.173.5.3310","article-title":"The cholera toxin-derived CTA1-DD vaccine adjuvant administered intranasally does not cause inflammation or accumulate in the nervous tissues","volume":"173","author":"Eriksson","year":"2004","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2014.02.056_bib0115","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1046\/j.1462-5822.2003.00338.x","article-title":"From toxin to adjuvant: the rational design of a vaccine adjuvant vector CTA1-DD\/ISCOM","volume":"6","author":"Lycke","year":"2004","journal-title":"Cell Microbiol"},{"key":"10.1016\/j.vaccine.2014.02.056_bib0120","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/1756-3305-6-63","article-title":"Compound DNA vaccine encoding SAG1\/SAG3 with A2\/B subunit of cholera toxin as a genetic adjuvant protects BALB\/c mice against Toxoplasma gondii","volume":"6","author":"Cong","year":"2013","journal-title":"Parasit Vectors"},{"key":"10.1016\/j.vaccine.2014.02.056_bib0125","doi-asserted-by":"crossref","first-page":"P294","DOI":"10.1186\/1742-4690-6-S3-P294","article-title":"Immunogenicity comparison of DNA vaccines encompassing HIV-1 tat, rev, integrase (C-half), vif and nef genes derived from different clades","volume":"6","author":"Wan","year":"2009","journal-title":"Retrovirology"},{"key":"10.1016\/j.vaccine.2014.02.056_bib0130","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1084\/jem.185.7.1203","article-title":"Mutants in the ADP-ribosyltransferase cleft of cholera toxin lack diarrheagenicity but retain adjuvanticity","volume":"185","author":"Yamamoto","year":"1997","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2014.02.056_bib0135","doi-asserted-by":"crossref","first-page":"4949","DOI":"10.1016\/j.vaccine.2007.01.118","article-title":"Comparison of immunogenicity between codon optimized HIV-1 Thailand subtype B gp140 and gp145 vaccines","volume":"25","author":"Wan","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.02.056_bib0140","first-page":"3381","article-title":"Establishing a Th17 based mouse model for preclinical assessment of the toxicity of candidate microbicides","volume":"123","author":"Li","year":"2010","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.vaccine.2014.02.056_bib0145","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2(\u2212Delta Delta C(T)) method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"key":"10.1016\/j.vaccine.2014.02.056_bib0150","doi-asserted-by":"crossref","first-page":"e3323","DOI":"10.1371\/journal.pone.0003323","article-title":"Robust intrapulmonary CD8 T cell responses and protection with an attenuated N1L deleted vaccinia virus","volume":"3","author":"Mathew","year":"2008","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2014.02.056_bib0155","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.ejphar.2012.05.007","article-title":"Pretreatment with interleukin-6 small interfering RNA can improve the survival rate of polymicrobial cecal ligation and puncture mice by down regulating interleukin-6 production","volume":"688","author":"Mostafa","year":"2012","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.vaccine.2014.02.056_bib0160","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jbiotec.2012.08.012","article-title":"The future of human DNA vaccines","volume":"162","author":"Li","year":"2012","journal-title":"J Biotechnol"},{"key":"10.1016\/j.vaccine.2014.02.056_bib0165","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s12026-008-8076-3","article-title":"DNA vaccines: developing new strategies to enhance immune responses","volume":"42","author":"Abdulhaqq","year":"2008","journal-title":"Immunol Res"},{"key":"10.1016\/j.vaccine.2014.02.056_bib0170","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S1046-2023(03)00140-3","article-title":"Adjuvant formulations and delivery systems for DNA vaccines","volume":"31","author":"Sasaki","year":"2003","journal-title":"Methods"},{"key":"10.1016\/j.vaccine.2014.02.056_bib0175","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/ijc.24333","article-title":"Enhancement of immunogenicity of a therapeutic cervical cancer DNA-based vaccine by co-application of sequence-optimized genetic adjuvants","volume":"125","author":"Ohlschlager","year":"2009","journal-title":"Int J Cancer"},{"key":"10.1016\/j.vaccine.2014.02.056_bib0180","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1002\/eji.200939271","article-title":"Marked enhancement of antigen-specific T-cell responses by IL-7-fused nonlytic, but not lytic, Fc as a genetic adjuvant","volume":"40","author":"Nam","year":"2010","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.vaccine.2014.02.056_bib0185","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/j.vaccine.2009.11.058","article-title":"Effect of genetic adjuvants on immune respondance, growth and hormone levels in somatostatin DNA vaccination-induced Hu lambs","volume":"28","author":"Xue","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.02.056_bib0190","doi-asserted-by":"crossref","first-page":"7743","DOI":"10.1128\/JVI.00747-10","article-title":"HIV-1 protease has a genetic T-cell adjuvant effect which is negatively regulated by proteolytic activity","volume":"84","author":"Kim","year":"2010","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2014.02.056_bib0195","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1479-0556-8-4","article-title":"Development of avian influenza virus H5 DNA vaccine and MDP-1 gene of Mycobacterium bovis as genetic adjuvant","volume":"8","author":"Jalilian","year":"2010","journal-title":"Genet Vaccines Ther"},{"key":"10.1016\/j.vaccine.2014.02.056_bib0200","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/mt.2010.268","article-title":"DAI (DLM-1\/ZBP1) as a genetic adjuvant for DNA vaccines that promotes effective antitumor CTL immunity","volume":"19","author":"Lladser","year":"2011","journal-title":"Mol Ther"},{"key":"10.1016\/j.vaccine.2014.02.056_bib0205","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1016\/j.vaccine.2012.01.004","article-title":"Protective immune response against Toxoplasma gondii elicited by a recombinant DNA vaccine with a novel genetic adjuvant","volume":"30","author":"Zhou","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.02.056_bib0210","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.0105-2896.2006.00395.x","article-title":"Functional signatures of protective antiviral T-cell immunity in human virus infections","volume":"211","author":"Harari","year":"2006","journal-title":"Immunol Rev"},{"key":"10.1016\/j.vaccine.2014.02.056_bib0215","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1073\/pnas.1105771109","article-title":"Cholera toxin activates nonconventional adjuvant pathways that induce protective CD8 T-cell responses after epicutaneous vaccination","volume":"109","author":"Olvera-Gomez","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"June (28)","key":"10.1016\/j.vaccine.2014.02.056_bib0220","doi-asserted-by":"crossref","first-page":"4259","DOI":"10.1016\/j.vaccine.2012.04.013","article-title":"Preclinical safety evaluation of DNA vaccines encoding modified HPV16 E6 and E7","volume":"30","author":"Henken","year":"2012","journal-title":"Vaccine"},{"issue":"August (4)","key":"10.1016\/j.vaccine.2014.02.056_bib0225","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1089\/vim.2012.0015","article-title":"Hemokinin-1 as an adjuvant molecule enhancing humoral and memory responses to HBsAg DNA vaccination","volume":"25","author":"Chen","year":"2012","journal-title":"Viral Immunol"},{"issue":"December (11)","key":"10.1016\/j.vaccine.2014.02.056_bib0230","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1002\/ijc.27534","article-title":"Induction of proapoptotic antibodies to triple-negative breast cancer by vaccination with TRAIL death receptor DR5 DNA","volume":"131","author":"Piechocki","year":"2012","journal-title":"Int J Cancer"},{"issue":"April (7)","key":"10.1016\/j.vaccine.2014.02.056_bib0235","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1158\/0008-5472.CAN-09-2548","article-title":"A better immune reaction to Erbb-2 tumors is elicited in mice by DNA vaccines encoding rat\/human chimeric proteins","volume":"70","author":"Quaglino","year":"2010","journal-title":"Cancer Res"},{"issue":"October (4)","key":"10.1016\/j.vaccine.2014.02.056_bib0240","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1084\/jem.184.4.1555","article-title":"Gene vaccination with naked plasmid DNA: mechanism of CTL priming","volume":"184","author":"Corr","year":"1996","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2014.02.056_bib0245","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.4049\/jimmunol.146.9.2908","article-title":"Cholera toxin stimulates IL-1 production and enhances antigen presentation by macrophages in vitro","volume":"146","author":"Bromander","year":"1991","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2014.02.056_bib0250","doi-asserted-by":"crossref","first-page":"4637","DOI":"10.1128\/IAI.61.11.4637-4644.1993","article-title":"Enhancing effect of cholera toxin on interleukin-6 secretion by IEC-6 intestinal epithelial cells: mode of action and augmenting effect of inflammatory cytokines","volume":"61","author":"McGee","year":"1993","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2014.02.056_bib0255","doi-asserted-by":"crossref","first-page":"316","DOI":"10.4049\/jimmunol.156.1.316","article-title":"Cholera toxin increases IL-6 synthesis and decreases TNF-alpha production by rat peritoneal mast cells","volume":"156","author":"Leal-Berumen","year":"1996","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2014.02.056_bib0260","doi-asserted-by":"crossref","first-page":"e5190","DOI":"10.1371\/journal.pone.0005190","article-title":"Intranasal delivery of cholera toxin induces th17-dominated T-cell response to bystander antigens","volume":"4","author":"Lee","year":"2009","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2014.02.056_bib0265","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/S1043-4666(03)00224-2","article-title":"Differential regulation of TNF-alpha IL-6 and IL-10 in UVB-irradiated human keratinocytes via cyclic AMP\/protein kinase A pathway","volume":"23","author":"Grandjean-Laquerriere","year":"2003","journal-title":"Cytokine"},{"key":"10.1016\/j.vaccine.2014.02.056_bib0270","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1038\/ki.1995.475","article-title":"Interleukin-1-induced IL-8 and IL-6 gene expression and production in human mesangial cells is differentially regulated by cAMP","volume":"48","author":"Robson","year":"1995","journal-title":"Kidney Int"},{"key":"10.1016\/j.vaccine.2014.02.056_bib0275","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.4049\/jimmunol.165.5.2850","article-title":"Distribution of DNA vaccines determines their immunogenicity after intramuscular injection in mice","volume":"165","author":"Dupuis","year":"2000","journal-title":"J Immunol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X14002412?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X14002412?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T03:50:44Z","timestamp":1689047444000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X14002412"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4]]},"references-count":55,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["S0264410X14002412"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2014.02.056","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"As a genetic adjuvant, CTA improves the immunogenicity of DNA vaccines in an ADP-ribosyltransferase activity- and IL-6-dependent manner","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2014.02.056","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}